Public Release: 

Most CRT-P patients would not benefit from addition of defibrillator

European Society of Cardiology

London, UK - 1 Sept 2015: Most patients with a cardiac resynchronisation therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented for the first time today at ESC Congress1 and published in European Heart Journal.2

"The choice between CRT with (CRT-D) or without (CRT-P) a defibrillator remains a contentious issue," said Professor Jean-Yves Le Heuzey, cardiologist at Georges Pompidou Hospital, René Descartes University in Paris, France. "No randomised clinical trial has been conducted to guide this choice."

Patients with congestive heart failure are at high risk of dying from sudden cardiac death. Over the last decade, CRT and implantable cardioverter defibrillators (ICDs) have markedly improved prognosis. Guidelines do not make firm recommendations on the choice of CRT-P versus CRT-D, stating that there is insufficient evidence from randomised controlled trials to show that CRT-D would additionally improve survival compared to CRT-P.3 This has left room for physician discretion and resulted in wide variation in worldwide implantation rates. For instance, the proportion of CRT implantations which are CRT-D reaches more than 90% in the US whereas it is lesser across Europe.

"Whether such a high rate of CRT-D use over CRT-P is justified is an important question to answer in terms of significant costs and device-related complications," said Professor Le Heuzey. "ICD lead failures, inappropriate shocks and risk of infection are real problems with impacts on quality of life and possibly survival. But the ideal way to answer this question, a randomised controlled trial directly comparing CRT-P to CRT-D, would have to be large, expensive and is unlikely to ever be conducted."

The CeRtiTuDe study evaluated the characteristics of CRT-P versus CRT-D patients in a real-world scenario and analysed to what extent CRT-P patients would have benefited from the presence of a back-up defibrillator. It was a multicentre prospective follow-up cohort study that enrolled a total of 1 705 consecutive patients implanted with a CRT (CRT-P 535; CRT-D 1 170) between 2008 and 2010 in France. Adjudication for causes of death was conducted at two years follow up.

Patients with CRT-P compared to CRT-D (Figure 1) were older (75.9 vs 65.6 years, p<0.0001), less often male (69.5 vs 80.8%, p<0.0001), more symptomatic (proportion of NYHA class III/IV, 88 vs 80%, p=0.002), with less coronary artery disease (40.7 vs 49.3%, p=0.003), wider QRS (161 ± 29 vs 155 ± 26 msec, p=0.002), more atrial fibrillation (38.7 vs 22.1%, p<0.0001) and more comorbidities (? 2 comorbidities 16.9 vs 12.9 %, p=0.04).

At two year follow up 267 patients had died, giving an annual overall mortality rate of 83.8 per 1 000. The crude mortality rate among CRT-P patients was double compared to CRT-D (relative risk [RR]=2.01, 95% confidence interval[CI]=1.56-2.58). "By cause-of-death analysis, 95% of the excess mortality among CRT-P subjects was related to an increase of non-sudden death," said Professor Le Heuzey. "This could indicate that this excess mortality is due to heart failure and non cardiovascular events."

He concluded: "Our findings suggest that patients selected for CRT-P in routine clinical practice would not benefit from the addition of a defibrillator. This indicates that CRT-D rates could be reduced, with consequent decreases in costs and device-related complications."

###

Figure 1: Clinical profile of CRT-P and CRT-D recipients

DCM=(non ischaemic) dilated cardiomyopathy; AF=atrial fibrillation

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.